<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155738</url>
  </required_header>
  <id_info>
    <org_study_id>PFD-C-14-009</org_study_id>
    <nct_id>NCT02155738</nct_id>
  </id_info>
  <brief_title>IV Acetaminophen for Postoperative Pain After Pelvic Organ Prolapse Repair</brief_title>
  <official_title>The Impact of IV Acetaminophen on Postoperative Pain in Women Undergoing Pelvic Organ Prolapse Repair: A Double-Blind Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halina M Zyczynski, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preoperative IV Acetaminophen reduces
      postoperative pain and narcotic consumption in women undergoing surgical repair of pelvic
      organ prolapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial of IV Acetaminophen compared to placebo will evaluate the
      effect of preoperative IV Acetaminophen on postoperative pain scores and narcotic
      requirements in women undergoing surgical repair of pelvic organ prolapse. 204 women will
      randomly receive 1000 mg of IV Acetaminophen or saline preoperatively within 30 minutes of
      surgical incision. Subjects will be offered narcotic and non-narcotic pain medications as
      needed during the postoperative period. Visual analogue pain scales (VAS) will be obtained at
      4, 8, 12, 16, 20 and 24 hours postoperatively. Narcotic consumption will be recorded in
      morphine-equivalents. We hypothesize that women receiving IV Acetaminophen will have lower
      VAS scores and decreased narcotic requirements compared to controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Postoperative Pain</measure>
    <time_frame>24 hours</time_frame>
    <description>VAS or Visual Analog Score is a quantitative measure, in this study, of pain that the subject is currently experiencing. The VAS is presented as a straight line which measures 100mm. The subject is instructed to mark an 'X' through this line reflecting the amount of pain that they are currently experiencing. Zero would indicate no pain, while '100' would indicate the most severe pain ever. Thus the total range for this scale would be 0-100 mm. Higher values indicate more pain; lower value indicate less pain.
For this outcome measure, the VAS scores from Baseline and the VAS scores from 24 hours after the end of surgery are being used. The change from baseline in postoperative pain equals the 24 hour VAS score minus the baseline VAS score.
The Change from Baseline would be the 24-hour VAS score minus the Baseline VAS score. Higher values indicate more pain; lower values indicate less pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Narcotic Consumption Over the First 24 Hours</measure>
    <time_frame>First 24 hours</time_frame>
    <description>Equianalgesic dosage tables will be used to convert intra- and postoperative narcotics into morphine equivalents to compare narcotic requirements for the first week after surgery. Higher numbers indicate higher narcotic usage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interference of Pain With Physical, Mental and Social Activities</measure>
    <time_frame>1 week</time_frame>
    <description>Interference of pain with physical, mental and social activities will be measured by the Patient Reported Outcomes Measures Information Systems-Pain Interference-Short Form 8a (PROMIS PI-SF-8a) administered on POD#7.
This instrument measures the self reported consequences of pain on relevant aspects of one's life. This scale is considered to be universal rather than disease specific. Each question has five response options ranging in value from 1-5. The total raw score for the scale is the sum of all values. The total raw score can range from 8-40. All questions much be answered to obtain a valid score.
A higher PROMIS score indicates more 'hurt' or pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV normal saline</intervention_name>
    <description>IV normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ≥ 18 years of age

          -  scheduled to undergo surgery for POP via a vaginal or minimally invasive
             (laparoscopic/robotic) route at the University of Pittsburgh Medical Center

          -  women anticipated to have a hospital stay ≥24 hours

        Exclusion Criteria:

          -  allergy/intolerance to acetaminophen

          -  hepatic dysfunction

          -  significant alcohol use - defined as patient reported consumption of more than 7
             standard drinks per week and/or 3 drinks per day
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Magee-Womens Hospital of the University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>August 28, 2018</results_first_submitted>
  <results_first_submitted_qc>October 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2018</results_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Halina M Zyczynski, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>IV acetaminophen</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Pelvic organ prolapse surgery</keyword>
  <keyword>Pelvic organ prolapse repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02155738/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women were recruited form the Urogynecology offices of the University of Pittsburgh Medical Center (UPMC) and Allegheny Health Network (AHN) from July 2014 - August 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaginal Surgery - Placebo</title>
          <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent vaginal surgery.</description>
        </group>
        <group group_id="P2">
          <title>Vaginal Surgery - IV Acetaminophen</title>
          <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent vaginal surgery.</description>
        </group>
        <group group_id="P3">
          <title>Laparoscopic Surgery - Placebo</title>
          <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent laparoscopic surgery.</description>
        </group>
        <group group_id="P4">
          <title>Laparoscopic Surgery - IV Acetaminophen</title>
          <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent laparoscopic surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing critical information</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject in the Vaginal Surgery - Placebo group, and one subject in the Laparoscopic Surgery - IV Acetaminophen group did not complete the study. (Missing critical information: (1) information from the pharmacy regarding group assignment; (2) signed informed consent form.</population>
      <group_list>
        <group group_id="B1">
          <title>Vaginal Surgery - Placebo</title>
          <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent vaginal surgery.</description>
        </group>
        <group group_id="B2">
          <title>Vaginal Surgery - IV Acetaminophen</title>
          <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent vaginal surgery.</description>
        </group>
        <group group_id="B3">
          <title>Laparoscopic Surgery - Placebo</title>
          <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent laparoscopic surgery.</description>
        </group>
        <group group_id="B4">
          <title>Laparoscopic Surgery - IV Acetaminophen</title>
          <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent laparoscopic surgery.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.24" spread="10.87"/>
                    <measurement group_id="B2" value="70.5" spread="9.20"/>
                    <measurement group_id="B3" value="60.22" spread="8.00"/>
                    <measurement group_id="B4" value="62.08" spread="7.00"/>
                    <measurement group_id="B5" value="65.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="202"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Postmenopausal</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <description>Parity refers to the number of times the subject gave birth to a baby more than 20 weeks gestation. Parity is expressed as a whole number.</description>
          <units>births</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B2" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B4" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B5" value="2" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline POPQ Stage</title>
          <description>POP-Q Stage is the Pelvic Organ Prolapse Quantification Stage. This is a whole number which refers to the extend of the prolapse, and how far past the hymen it extends. POP-Q Stage is a whole number between 1 and 4. Stage 1 is prolapse which is fully contained within the vagina and above the hymen. Stage 4 is prolapse which extends at least 3 cm beyond the hymen.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline VAS Pain Score</title>
          <description>VAS or Visual Analog Score is a quantitative measure, in this study, of pain that the subject is currently experiencing. The VAS is presented as a straight line which measures 100mm. The subject is instructed to mark an 'X' through this line reflecting the amount of pain that they are currently experiencing. Zero would indicate no pain, while '100' would indicate the most severe pain ever. Thus the total range for this scale would be 0-100 mm. Higher values indicate more pain; lower value indicate less pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.32" spread="15.73"/>
                    <measurement group_id="B2" value="3.41" spread="8.71"/>
                    <measurement group_id="B3" value="5.57" spread="15.60"/>
                    <measurement group_id="B4" value="6.91" spread="12.75"/>
                    <measurement group_id="B5" value="5.75" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Postoperative Pain</title>
        <description>VAS or Visual Analog Score is a quantitative measure, in this study, of pain that the subject is currently experiencing. The VAS is presented as a straight line which measures 100mm. The subject is instructed to mark an 'X' through this line reflecting the amount of pain that they are currently experiencing. Zero would indicate no pain, while '100' would indicate the most severe pain ever. Thus the total range for this scale would be 0-100 mm. Higher values indicate more pain; lower value indicate less pain.
For this outcome measure, the VAS scores from Baseline and the VAS scores from 24 hours after the end of surgery are being used. The change from baseline in postoperative pain equals the 24 hour VAS score minus the baseline VAS score.
The Change from Baseline would be the 24-hour VAS score minus the Baseline VAS score. Higher values indicate more pain; lower values indicate less pain.</description>
        <time_frame>24 hours</time_frame>
        <population>The number of participants analyzed is less than the total starting the study in each group; data is missing. Missing data indicates that a 24 hour VAS was not obtained from the subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaginal Surgery - Placebo</title>
            <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent vaginal surgery.</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Surgery - IV Acetaminophen</title>
            <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent vaginal surgery.</description>
          </group>
          <group group_id="O3">
            <title>Laparoscopic Surgery - Placebo</title>
            <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent laparoscopic surgery.</description>
          </group>
          <group group_id="O4">
            <title>Laparoscopic Surgery - IV Acetaminophen</title>
            <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent laparoscopic surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postoperative Pain</title>
          <description>VAS or Visual Analog Score is a quantitative measure, in this study, of pain that the subject is currently experiencing. The VAS is presented as a straight line which measures 100mm. The subject is instructed to mark an 'X' through this line reflecting the amount of pain that they are currently experiencing. Zero would indicate no pain, while '100' would indicate the most severe pain ever. Thus the total range for this scale would be 0-100 mm. Higher values indicate more pain; lower value indicate less pain.
For this outcome measure, the VAS scores from Baseline and the VAS scores from 24 hours after the end of surgery are being used. The change from baseline in postoperative pain equals the 24 hour VAS score minus the baseline VAS score.
The Change from Baseline would be the 24-hour VAS score minus the Baseline VAS score. Higher values indicate more pain; lower values indicate less pain.</description>
          <population>The number of participants analyzed is less than the total starting the study in each group; data is missing. Missing data indicates that a 24 hour VAS was not obtained from the subject.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="23.1"/>
                    <measurement group_id="O2" value="29.2" spread="28.3"/>
                    <measurement group_id="O3" value="20.7" spread="24.6"/>
                    <measurement group_id="O4" value="20.1" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Aim 1: Quantify the impact of IV acetaminophen on 1a) postoperative pain scores ... 1a) To achieve this aim, we will measure the degree of postoperative pain using visual analog scales (VAS) at multiple specified time points throughout the postoperative period; we report on change from Baseline VAS at 24 Hours Postop. Null Hypothesis is that there is no difference between subgroups in VAS scores. Sample size was determined considering significant differences in VAS scores.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Narcotic Consumption Over the First 24 Hours</title>
        <description>Equianalgesic dosage tables will be used to convert intra- and postoperative narcotics into morphine equivalents to compare narcotic requirements for the first week after surgery. Higher numbers indicate higher narcotic usage.</description>
        <time_frame>First 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaginal Surgery - Placebo</title>
            <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent vaginal surgery.</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Surgery - IV Acetaminophen</title>
            <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent vaginal surgery.</description>
          </group>
          <group group_id="O3">
            <title>Laparoscopic Surgery - Placebo</title>
            <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent laparoscopic surgery.</description>
          </group>
          <group group_id="O4">
            <title>Laparoscopic Surgery - IV Acetaminophen</title>
            <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent laparoscopic surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Narcotic Consumption Over the First 24 Hours</title>
          <description>Equianalgesic dosage tables will be used to convert intra- and postoperative narcotics into morphine equivalents to compare narcotic requirements for the first week after surgery. Higher numbers indicate higher narcotic usage.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="24.7"/>
                    <measurement group_id="O2" value="31.6" spread="23.6"/>
                    <measurement group_id="O3" value="47.4" spread="24.2"/>
                    <measurement group_id="O4" value="44.5" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1b) We will use equianalgesic dosage tables to convert intra- and postoperative narcotics into morphine equivalents to compare narcotic requirements for the first week after surgery. We hypothesize that those patients receiving preemptive IV acetaminophen will have lower postoperative VAS scores and reduced narcotic requirements compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interference of Pain With Physical, Mental and Social Activities</title>
        <description>Interference of pain with physical, mental and social activities will be measured by the Patient Reported Outcomes Measures Information Systems-Pain Interference-Short Form 8a (PROMIS PI-SF-8a) administered on POD#7.
This instrument measures the self reported consequences of pain on relevant aspects of one's life. This scale is considered to be universal rather than disease specific. Each question has five response options ranging in value from 1-5. The total raw score for the scale is the sum of all values. The total raw score can range from 8-40. All questions much be answered to obtain a valid score.
A higher PROMIS score indicates more 'hurt' or pain.</description>
        <time_frame>1 week</time_frame>
        <population>The number of participants analyzed is less than the total starting the study in each group; data is missing. Missing data indicates that the PROMIS PI-SF-8A was not received from the subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaginal Surgery - Placebo</title>
            <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent vaginal surgery.</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Surgery - IV Acetaminophen</title>
            <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent vaginal surgery.</description>
          </group>
          <group group_id="O3">
            <title>Laparoscopic Surgery - Placebo</title>
            <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent laparoscopic surgery.</description>
          </group>
          <group group_id="O4">
            <title>Laparoscopic Surgery - IV Acetaminophen</title>
            <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent laparoscopic surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Interference of Pain With Physical, Mental and Social Activities</title>
          <description>Interference of pain with physical, mental and social activities will be measured by the Patient Reported Outcomes Measures Information Systems-Pain Interference-Short Form 8a (PROMIS PI-SF-8a) administered on POD#7.
This instrument measures the self reported consequences of pain on relevant aspects of one's life. This scale is considered to be universal rather than disease specific. Each question has five response options ranging in value from 1-5. The total raw score for the scale is the sum of all values. The total raw score can range from 8-40. All questions much be answered to obtain a valid score.
A higher PROMIS score indicates more 'hurt' or pain.</description>
          <population>The number of participants analyzed is less than the total starting the study in each group; data is missing. Missing data indicates that the PROMIS PI-SF-8A was not received from the subject.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="0.15"/>
                    <measurement group_id="O2" value="22.0" spread="11.9"/>
                    <measurement group_id="O3" value="22.9" spread="8.1"/>
                    <measurement group_id="O4" value="25.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from day of surgery until 6 weeks postop.</time_frame>
      <desc>SAEs were defined a priori as readmissions to the hospital for any reason within 6 weeks of surgery. All subject medical records were reviewed to discover these events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vaginal Surgery - Placebo</title>
          <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent vaginal surgery.</description>
        </group>
        <group group_id="E2">
          <title>Vaginal Surgery - IV Acetaminophen</title>
          <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent vaginal surgery.</description>
        </group>
        <group group_id="E3">
          <title>Laparoscopic Surgery - Placebo</title>
          <description>100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV normal saline
These subjects underwent laparoscopic surgery.</description>
        </group>
        <group group_id="E4">
          <title>Laparoscopic Surgery - IV Acetaminophen</title>
          <description>100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
IV Acetaminophen
These subjects underwent laparoscopic surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Readmission within 6 weeks of surgery</sub_title>
                <description>Any readmission within 6 weeks of surgery. Medical records for all subjects were reviewed to discover these events.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Halina Zyczynski</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-641-1440</phone>
      <email>hzyczynski@mail.magee.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

